水蒸气消融治疗前列腺癌:VAPOR 2 研究初步消融疗效与毒性结果
VAPOR 2 是一项前瞻性多中心单臂研究,纳入 235 例中危局限性前列腺癌(PCa)患者,本文分析完成 12 个月随访的 110 例。6 个月活检显示靶向取样区仅良性组织占 75%,良性或 Gleason 分级组 1 占 91%,PSA 中位下降 58%,围术期不良事件多轻微且无直肠损伤。
要点
- 水蒸气消融对中危局限性 PCa 显示有效组织消融,6 个月活检仅良性组织达 75%。
- PSA 中位下降 58%,前列腺体积中位减少 8 cc,排尿与性功能先降后 12 个月内逐渐恢复。
- 围术期不良事件多轻微且无后遗症,未报告直肠损伤。
核心结论
- VAPOR 2 研究显示水蒸气消融对局限性中危 PCa 可实现有效组织消融,且操作相关并发症发生率低。
研究设计与样本
- 前瞻性、多中心、单臂研究(VAPOR 2),在美国 26 个中心纳入 235 例 ≥50 岁男性。
- 入组条件为 Gleason 分级组 2 PCa、多参数 MRI 融合活检单一 PI-RADS 3 或 4 异常、PSA ≤15 ng/mL、临床分期 ≤T2c。
- 本次报告为预设亚组分析,仅评估完成 12 个月随访的 110 例患者的消融疗效与毒性。
主要发现
- 中位年龄 65 岁,中位基线 PSA 5.6 ng/mL,中位前列腺体积 40.7 cc。
- 6 个月活检靶向取样治疗区域仅见良性组织者占 75%,良性组织或 Gleason 分级组 1 PCa 者占 91%。
- 回归分析未发现阳性活检的显著基线预测因素。
- PSA 中位下降 58%,前列腺体积中位减少 8 cc。
- 排尿与性功能在 12 个月内先下降后逐渐恢复;围术期不良事件多轻微且无后遗症,未报告直肠损伤。
临床怎么用
- 对于符合入组条件的中危局限性 PCa 患者,水蒸气消融可作为组织消融的候选方案,需告知 6 个月活检结果与功能恢复过程。
局限性
- 本次分析为单臂研究预设亚组的 110 例 12 个月随访数据,仅评估消融疗效与毒性,未报告肿瘤控制结局。
- 3 年随访将评估 PCa 管理疗效,总随访 5 年。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: The safety and effectiveness of water vapor for ablation of prostate tissue was assessed in men with intermediate-risk localized prostate cancer (PCa). MATERIALS AND METHODS: A prospective, multicenter, single-arm study (VAPOR 2) was conducted in 235 men at 26 centers across the United States in men ≥ 50 years, with Gleason Grade Group 2 PCa confined to a single Prostate Imaging Reporting and Data System 3 or 4 abnormality on multiparametric MRI fusion biopsy, PSA level ≤ 15 ng/mL, and clinical stage ≤ T2c. Data presented are a predefined subset analysis of 110 men completing 12-month follow-up to assess only ablative efficacy and toxicity. Reported outcomes include biopsy 6 months post treatment PSA, prostate volume reduction, urinary/sexual function, quality-of-life questionnaires, and adverse events. The 3-year follow-up analysis will evaluate efficacy in PCa management, with 5 years of total follow-up. RESULTS: The median age was 65 years, with a median baseline PSA of 5.6 ng/mL and prostate volume of 40.7 cc. On 6-month biopsy, targeted sampling of the treated region revealed benign tissue only in 75% and benign tissue or Gleason Grade Group 1 PCa in 91%. Regression analysis did not identify a significant baseline predictor of positive biopsy. PSA showed a median reduction of 58%, with a median 8 cc reduction in prostate volume. Urinary and sexual function showed an initial decline followed by gradual recovery through 12 months. Perioperative adverse events were generally mild and resolved without sequelae, with no reports of rectal injury. CONCLUSIONS: The VAPOR 2 study demonstrated effective ablation of prostate tissue in men with localized, intermediate-risk PCa with low rates of procedural morbidity.
引用
- George A, Giesler E, Mazzarella B, et al. Water Vapor Therapy for the Management of Prostate Cancer: The VAPOR 2 Study Initial Results of Ablative Efficacy and Toxicity. J Urol. 2026. PMID: 42269147. doi:10.1097/JU.0000000000005156
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。